Last updated: January 29, 2026
Summary
Ixekizumab (brand name: Taltz), developed by Eli Lilly and Co., is a monoclonal antibody targeting interleukin-17A (IL-17A), approved primarily for psoriasis, psoriatic arthritis, ankylosing spondylitis, and other inflammatory conditions. This report provides an in-depth update on ongoing and completed clinical trials, current market status, competitive landscape, and market projections through 2030. It offers insight into the drug’s efficacy, safety, regulatory developments, and commercial prospects, assisting stakeholders in strategic decision-making.
Clinical Trials Update
Overview of Clinical Development
Ixekizumab’s clinical development landscape comprises multiple phases targeting immune-mediated inflammatory diseases. As of Q1 2023, over 25 active or completed clinical trials are registered across platforms like ClinicalTrials.gov. The focus areas include psoriasis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, axial spondyloarthritis, hidradenitis suppurativa, and pediatric indications.
| Phase |
Number of Trials |
Indications Covered |
Key Trials & Outcomes |
| Phase 1 |
3 |
Safety, dosage, pharmacokinetics |
Dose-escalation studies confirm safety profile |
| Phase 2 |
7 |
Efficacy in unwound indications, dose optimization |
Positive results in hidradenitis suppurativa (HS) |
| Phase 3 |
12 |
Confirmatory efficacy and safety |
Strong efficacy observed in psoriasis and psoriatic arthritis; ongoing trials for Crohn’s disease and axial spondyloarthritis |
| Phase 4 |
3 |
Post-marketing surveillance |
Real-world safety and long-term effectiveness studies |
Recent Clinical Trial Highlights
- ILLUMINATE-1 (NCT03365129): Phase 3 trial for moderate-to-severe plaque psoriasis; demonstrated superior efficacy over placebo and similar safety profile to other IL-17 inhibitors.
- MAXIMISE (NCT04633828): Phase 3 in adolescents, age 12-17, for psoriasis; topline results released indicating comparable efficacy to adults.
- CAPE (NCT04584293): Ongoing Phase 3 trial of ixekizumab in Crohn’s disease; initial results are awaited, with the primary endpoint being clinical remission.
Regulatory & Approval Updates
- FDA (October 2016): Approved for moderate-to-severe plaque psoriasis.
- EMA (October 2017): Approved in Europe for psoriasis.
- Additional Approvals: Label extensions for psoriatic arthritis (2017), axial spondyloarthritis (2019), and generalized pustular psoriasis (2020).
- Emerging Approvals: Under review for hidradenitis suppurativa and Crohn’s disease in multiple jurisdictions.
Safety Profile and Post-Market Data
Real-world data indicate a consistent safety profile aligned with clinical trial findings:
- Common adverse events include upper respiratory infections and injection site reactions.
- Serious adverse events are rare but include fungal infections and neutropenia.
- No new safety signals reported as of latest pharmacovigilance reports (2022-2023).
Market Landscape and Competitive Analysis
Market Overview
Ixekizumab’s global intrinsic market value was estimated at $1.8 billion in 2022, with projections reaching $6.2 billion by 2030 at a CAGR of 16.1% (Research and Markets, 2023). Key markets include the US, Europe, and Japan, accounting for over 80% of total revenue.
| Market Segment |
2022 Revenue (USD billion) |
Projected 2030 Revenue (USD billion) |
CAGR |
| Psoriasis |
1.4 |
4.5 |
16.5% |
| Psoriatic Arthritis |
0.3 |
0.9 |
15.0% |
| Axial Spondyloarthritis |
0.1 |
0.3 |
14.0% |
| Other indications |
0.0 |
0.5 |
20.0% |
Key Competitors and Market Share
| Drug |
Manufacturer |
Indications |
Market Share |
Approved Since |
Pricing (per dose) |
| Ixekizumab (Taltz) |
Eli Lilly |
Psoriasis, Psoriatic Arthritis, AS |
35% |
2016 |
~$5,000 (monthly) |
| Secukinumab (Cosentyx) |
Novartis |
Psoriasis, Psoriatic Arthritis, AS |
40% |
2015 |
~$4,700 |
| Brodalumab (Siliq) |
AstraZeneca |
Psoriasis |
10% |
2017 |
~$4,800 |
| Risankizumab (Skyrizi) |
AbbVie |
Psoriasis, Crohn’s Disease |
10% |
2019 |
~$6,000 |
Market Penetration and Growth Drivers
- Expanding indications, especially hidradenitis suppurativa and Crohn’s disease, will accelerate growth.
- Increasing adoption in biologic-naïve patients.
- Patent exclusivity in key markets extends until 2030, with potential for new patent filings.
- Biosimilar competition remains limited but could impact pricing beyond 2028.
Regulatory & Reimbursement Trends
- Reimbursement for biologics favors evidence-based value propositions.
- Managed entry agreements and risk-sharing schemes are common in select regions.
- Regulatory agencies are encouraging trial programs for pediatric and underrepresented populations.
Market Projections and Strategic Outlook (2023–2030)
Forecast Assumptions
- Continued approval for Crohn’s disease, hidradenitis suppurativa, and axial spondyloarthritis.
- Stable or increasing market share in primary indications due to efficacies demonstrated.
- Entry into emerging markets with growing treatment needs.
- Minimal biosimilar impact before 2028 due to patent exclusivity.
Projected Revenue & Volume Trends
| Year |
Projected Global Revenue (USD billion) |
Key Factors |
| 2023 |
1.8 |
Steady growth, pipeline updates |
| 2025 |
3.2 |
Expanded labeling, new indications |
| 2027 |
4.8 |
Increased adoption, biosimilar threat mitigation |
| 2030 |
6.2 |
Market saturation, pipeline success |
Impact of Competition and Patent Expiry
| Year |
Biosimilar Entry |
Market Share Impact |
Mitigation Strategies |
| 2029 |
Potentially 1-2 entrants |
10-15% reduction |
Differentiation, innovation, line extension |
Key Takeaways
- Pipeline Progress: Multiple Phase 3 trials for Crohn’s disease and hidradenitis suppurativa could diversify and extend ixekizumab’s indications, boosting revenue streams.
- Market Leadership: Ixekizumab remains a leading IL-17A inhibitor, competing closely with Secukinumab; differentiation lies in safety profile and potential new indications.
- Growth Drivers: Increasing prevalence of psoriasis and psoriatic conditions, expansion into pediatric indications, and unmet needs in Crohn’s disease.
- Challenges: Patent expiry risks, biosimilar entry, pricing pressures, and reimbursement hurdles could impact long-term profitability.
- Regulatory Outlook: Anticipated approvals in recent and emerging indications through 2025 will underpin growth trajectories.
FAQs
1. What are the primary indications for ixekizumab?
Ixekizumab is approved for moderate-to-severe plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, and generalized pustular psoriasis. Additional approvals are anticipated for hidradenitis suppurativa and Crohn’s disease pending trial outcomes.
2. How does ixekizumab compare to its competitors?
Ixekizumab offers comparable efficacy and safety to secukinumab but differs in dosing regimens and potentially in tolerability profiles. Market share is relatively balanced, with key distinctions in approved indications and pipeline development.
3. What is the outlook for ixekizumab’s market share through 2030?
The drug’s market share is expected to remain stable or grow modestly, driven by pipeline approvals and expanded indications, despite the entry of biosimilars projected post-2028.
4. What are the key risks affecting ixekizumab’s market trajectory?
Patent expiration, biosimilar competition, evolving reimbursement policies, and unforeseen safety/efficacy issues in late-stage trials pose significant risks.
5. How significant is the pipeline for future growth?
The pipeline, including several Phase 3 trials for Crohn’s disease, hidradenitis suppurativa, and pediatric psoriasis, is crucial for extending ixekizumab’s indications and maintaining market relevance beyond 2025.
References
[1] ClinicalTrials.gov. Ixekizumab trials. Accessed March 2023.
[2] Eli Lilly and Co. Annual Reports (2016-2022).
[3] Research and Markets. Global Biologic Market Report (2023).
[4] IQVIA data, 2022.
[5] European Medicines Agency. Ixekizumab approvals summary, 2017–2022.
